A new study published in The American Journal of Human Genetics suggests that individualized genetic therapies could eventually treat larger groups of patients without requiring a new drug for every disease-causing mutation.Researchers studying SCN2A-related disorders found that two existing antisense oligonucleotides (ASOs) could potentially serve 10 of 21 patients analyzed. They also estimated that a panel of four ASOs could genetically match approximately 76% of individuals in a population reference dataset. The approach uses shared genetic markers, known as haplotypes, to selectively silence the disease-causing copy of a gene while preserving the healthy copy. This could allow patients with different causal mutations to receive the same ASO, provided they share the appropriate marker.
The findings are early, and additional ASOs require experimental validation. But they raise an important question for rare disease drug developers: if therapies can be developed for groups rather than individuals, how do sponsors identify and match the patients who could benefit?
Traditional N-of-1 genetic therapies are developed for individual patients whose mutations may be too rare to support conventional drug development. In 2019, researchers reported the development of milasen, a customized ASO for a child with CLN7 Batten disease, in approximately one year. More recently, Children's Hospital of Philadelphia reported the treatment of Baby KJ, an infant with CPS1 deficiency, using a bespoke gene-editing therapy developed in approximately six months. Both programs demonstrated the potential of individualized medicine, but developing a separate treatment for every mutation creates substantial scientific, manufacturing and financial challenges.
The SCN2A researchers propose a different approach. Rather than designing an ASO against each disease-causing mutation, they identified common genetic markers that distinguish the chromosome carrying a harmful SCN2A variant from the chromosome carrying the healthy copy. When a suitable marker sits on the same chromosome as the disease-causing variant, an ASO can target that copy of the gene. Patients with different mutations may therefore be compatible with the same treatment.
In their analysis, 10 of 21 patients had genetic profiles compatible with two previously developed ASOs. The researchers also identified 18 additional common SCN2A haplotypes and used computational modeling to investigate further candidates. Using genomic data from 2,504 participants in the 1000 Genomes Project, they estimated that a four-ASO panel could provide compatible genetic coverage for 76.2% of the reference population.
That figure represents modeled genetic compatibility, not demonstrated treatment eligibility or efficacy in patients with SCN2A disorders. The additional candidates require further validation, and patients would also need an appropriate disease mechanism. Nevertheless, the research points toward a potentially more scalable model: a library of pre-designed therapies that could be matched to patients based on their genetic profiles.
A haplotype library changes where some of the hardest work in precision medicine happens. In an N-of-1 program, much of the effort centers on developing a therapy for an individual patient. A library approach aims to complete more of that development in advance, making it possible to match multiple patients to the same treatment. But that efficiency depends on identifying the right patients.
For sponsors, a confirmed SCN2A diagnosis may not be enough to establish eligibility. Patients must also have a compatible disease mechanism and the appropriate genetic marker on the same chromosome as the disease-causing variant, a relationship known as in cis. Establishing this relationship requires genetic phasing, which determines how variants are distributed across the two copies of a chromosome.
The researchers used whole-genome sequencing and haplotype analysis to make these distinctions. In future clinical programs, sponsors would need to establish appropriate testing and phasing requirements before recruitment begins. Existing diagnostic reports may identify a pathogenic variant without providing the phased information needed for therapy matching, meaning some patients could require additional testing or reanalysis.
Recruitment would also become more complex. Rather than identifying patients carrying one specific mutation, sponsors would need to find people with relevant disease-causing variants, determine their haplotypes and assign them to the appropriate ASO-defined groups. This begins to resemble biomarker-driven basket-trial recruitment, with different genetic subgroups potentially receiving different therapies within a coordinated development program.
The central feasibility question becomes not simply how many patients have the condition, but how many can be identified, genetically matched and clinically qualified for an available treatment. That distinction is important for estimating eligible populations, planning testing strategies, and selecting recruitment sites.
A library approach could also change how sponsors think about patients who do not qualify for an existing therapy. Someone whose genetic profile does not match today's ASO panel may become eligible when additional treatments are developed and validated. Maintaining appropriate consent and keeping those patients engaged could support future research without restarting recruitment from the beginning.
This increases the value of registries, natural history studies and longitudinal cohorts that combine genetic information with ongoing patient engagement. It also highlights a persistent challenge in rare disease research: patients are geographically dispersed, and their genetic information may be held across multiple healthcare systems, laboratories and research programs. Building therapy-matched cohorts may therefore require coordinated testing, digital consent, remote participation and reliable patient recontact.
In an ultra-rare disease recruitment program supported by Sano, 14% of tested patients carried one of two target variants, while 42% carried related variants. More than 84% of non-target participants remained engaged for future studies through Sano's Virtual Waiting Room.
These examples illustrate why identifying and maintaining relationships with genetically characterized patients can be valuable beyond a single recruitment campaign.
Regulators are exploring how development pathways might accommodate therapies designed for very small patient populations. In February 2026, the FDA published its Plausible Mechanism Framework draft guidance, outlining considerations for individualized treatments, including RNA-based therapies and genome-editing products, when conventional randomized trials may not be feasible.
A second draft guidance, issued in October 2026, addresses how multiple variants of an individualized genome-editing product could be managed within a single Biologics License Application. Sponsors could define an Individualized Feature Space that establishes allowable variation between product versions, potentially enabling multiple patient-specific variants to be covered under one application.
The October guidance applies to genome-editing products, not ASO libraries, but both drafts reflect growing regulatory attention to development models that accommodate related individualized treatments. Our analysis of the FDA's genome-editing guidance examines why these approaches could bring patient identification earlier into development planning.
In the UK, the MHRA has also authorized a shared trial framework for EveryONE Medicines' individualized ASO program, allowing multiple personalized treatments to be evaluated within a common regulatory structure. While these developments do not establish a single pathway for haplotype-matched ASO libraries, they suggest increasing interest in making individualized genetic medicine more practical at scale.
The potential of haplotype-matched ASOs is encouraging, but the clinical evidence remains limited. Two children with SCN2A-related disorders received individualized ASOs in a 2026 Nature Medicine study. According to the FamilieSCN2A Foundation's review, one patient experienced an estimated 26% reduction in seizure frequency that was not statistically significant, while the second experienced a statistically significant 90% reduction in seizure counts. Improvements in some developmental and behavioral measures were also reported. These early findings support further investigation but cannot establish effectiveness across a broader population.
The proposed library requires additional laboratory validation, followed by appropriate nonclinical and clinical evaluation. Its modeled genetic coverage must also be assessed alongside the disease mechanisms and clinical characteristics of patients who might receive treatment.
Ancestry is another important consideration. Haplotype frequencies differ across populations, meaning a panel designed around common markers may not provide equivalent coverage across ancestry groups. The extent of any differences for the proposed four-ASO panel remains to be established. For sponsors, this could affect recruitment feasibility and equitable access, particularly if population-level coverage estimates do not reflect the patients available within specific countries or healthcare systems.
Future studies will also need to establish how new ASOs can be added to a library, what evidence can be shared across related treatments and whether the approach can extend to other genetic disorders. The authors propose potential applications in conditions involving gain-of-function and dominant-negative mechanisms, although each would require separate scientific validation.
The SCN2A findings suggest that precision therapies developed for individual patients may eventually become the foundation for treatments serving genetically defined groups. But scaling drug development does not automatically solve the challenge of reaching eligible patients.
For sponsors considering haplotype-based therapies, feasibility planning may need to account for genetic phasing, diagnostic data availability, population-level haplotype frequencies and the practical requirements of matching patients to different treatments. These considerations are most useful early in development, when testing strategies, eligibility criteria and recruitment plans can still be shaped around the target population.
As discussed in our analysis of BEAM-301 and genotype-first clinical trial feasibility, identifying patients with a relevant genetic variant is only the beginning of understanding the recruitable population. Haplotype-matched therapies add another layer to that challenge while creating opportunities to make better use of genetically characterized cohorts over time.
The promise of N-of-many medicine will depend on more than developing therapies that can serve multiple patients. It will also require the infrastructure to find those patients, establish eligibility and maintain engagement as new treatment options become available.
To discuss patient identification and genetic testing strategies for precision medicine trials, get in touch.